A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway
出版年份 2020 全文链接
标题
A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway
作者
关键词
-
出版物
BMC CANCER
Volume 20, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-01-01
DOI
10.1186/s12885-019-6169-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI
- (2018) Joel C. Wight et al. BLOOD REVIEWS
- Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
- (2018) Lan V. Pham et al. CLINICAL CANCER RESEARCH
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- PI3Kδ Inhibition Hits a Sensitive Spot in B Cell Malignancies
- (2014) Bart Vanhaesebroeck et al. CANCER CELL
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- BM-1197: A Novel and Specific Bcl-2/Bcl-xL Inhibitor Inducing Complete and Long-Lasting Tumor Regression In Vivo
- (2014) Longchuan Bai et al. PLoS One
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency
- (2012) Guo Wei et al. CANCER CELL
- Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
- (2011) A Smith et al. BRITISH JOURNAL OF CANCER
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
- (2011) Michael Pfreundschuh et al. LANCET ONCOLOGY
- A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
- (2011) Paul K. Paik et al. LUNG CANCER
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- (2011) J. W. Friedberg Hematology-American Society of Hematology Education Program
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
- (2010) B. Coiffier et al. BLOOD
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- BH3 Mimetic ABT-737 Potentiates TRAIL-Mediated Apoptotic Signaling by Unsequestering Bim and Bak in Human Pancreatic Cancer Cells
- (2008) S. Huang et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now